Respiratory failure following vinorelbine tartrate infusion in a patient with non-small cell lung cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 9315826.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Vinorelbine tartrate (Navelbine [Burroughs Wellcome; Research Triangle Park, NC; Pierre Fabre Medicament; Paris, France]) is used in the treatment of non-small cell lung cancer (NSCLC), breast cancer, and some gynecologic malignant neoplasms. The reported prevalence of adverse effects involving the respiratory system is less than 5% and involves mostly dyspnea with occasional interstitial infiltrates. A patient with a hypercoagulable state and diffuse pulmonary NSCLC developed acute respiratory failure soon after vinorelbine infusion. Physicians should be aware of possible increased pulmonary toxicity of vinorelbine in patients with diffuse pulmonary NSCLC.
Medical subject headings
- Antineoplastic Agents, Phytogenic
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Respiratory Insufficiency
- Vinblastine